Citius Pharmaceuticals Inc Stock Price, News & Analysis

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced its participation in two virtual conferences in January 2022. Presentations will be accessible on-demand beginning January 10, 2022. The events include the H.C. Wainwright BioConnect Conference from January 10-13 and Biotech Showcase™ 2022 on January 10-12 and 17-19. Archived webcasts will be available for 90 days on the Citius website. The company focuses on critical care products, including Mino-Lok® and I/ONTAK, both in late-stage development. For more details, visit www.citiuspharma.com.

Citius Pharmaceuticals (Nasdaq: CTXR) reported its fiscal year 2021 results, highlighting significant advancements and financial activities. The company completed the subject treatment in the pivotal Phase 3 trial of I/ONTAK and expects topline results in the first half of 2022, with a BLA submission set for the second half. They raised $120.6 million in financing, boosting cash reserves to $70.1 million. However, the net loss increased to $23.1 million, primarily due to rising R&D and G&A expenses. Citius is positioned for growth with a robust pipeline and anticipates multiple milestones in 2022.

Citius Pharmaceuticals, Inc. (CTXR) has completed patient enrollment in its pivotal Phase 3 trial for I/ONTAK, a treatment for recurrent cutaneous T-cell lymphoma (CTCL). With 70 patients enrolled, the study aims to evaluate the drug's efficacy and safety, with topline results expected in H1 2022. The biologics license application (BLA) is anticipated in H2 2022. I/ONTAK, a reformulation of the previously approved ONTAK, targets IL-2 receptors and has received orphan drug designation from the FDA. This marks a significant step in expanding treatment options for advanced CTCL patients.

Citius Pharmaceuticals, Inc. (CTXR) announced the appointment of Kelly Creighton, PhD, as Executive Vice President of Chemistry, Manufacturing and Controls. Dr. Creighton brings nearly two decades of pharmaceutical industry expertise, with over 50 investigational new drug submissions and 20 approved applications. He will oversee global regulatory and manufacturing strategies for Citius's five pipeline programs, as the company prepares for commercial success with two late Phase 3 trials nearing completion. Management expresses confidence in his ability to drive the company’s clinical development and regulatory pathways forward.

Citius Pharmaceuticals (Nasdaq: CTXR) announced a KOL webinar on November 11, 2021, at 11:30 AM ET addressing the salvage of central venous catheters in patients with CLABSI. Leading experts Issam Raad from MD Anderson and Mark Rupp from the University of Nebraska will discuss the unmet medical needs and the impact of COVID-19 on infection rates. Citius's Chief Medical Officer, Myron Czuczman, will provide updates on Mino-Lok®, their antibiotic treatment for catheter-related infections, currently in a Phase 3 clinical trial. Pre-registration is required for participation.

Citius Pharmaceuticals (Nasdaq: CTXR) will host a webcast on October 20, 2021, at 8:30 a.m. ET, to discuss its acquisition of I/ONTAK (E7777), an enhanced formulation of the immunotoxin ONTAK, previously FDA-approved for cutaneous T-cell lymphoma (CTCL). CEO Myron Holubiak and other executives will outline the company's strategy and the potential of I/ONTAK, which has received regulatory approval in Japan and orphan drug designation from the FDA. A pivotal study on I/ONTAK is underway, with results expected in mid-2022.

Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in two investor conferences in October 2021. The first event is the Benzinga Rising Stars Conference on October 7, 2021, where Executive Chairman Leonard Mazur will present at 9:05 a.m. ET. The second is the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021, with Mazur presenting at 8:55 a.m. ET. Citius is focused on critical care products in oncology, including late-stage assets like Mino-Lok^® and I/ONTAK (E7777).

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that Leonard Mazur, Executive Chairman, and his wife, Helena, were honored by Temple University, which renamed its main building for the College of Liberal Arts to Leonard and Helena Mazur Hall. This honor recognizes their significant contributions to the university and commitment to enhancing student opportunities. The event occurred on September 30, 2021, and underscores the Mazurs' role in supporting higher education and career development for students. Citius continues to focus on critical care products, including two late-stage therapies.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will join Benzinga's All Access Show for a 20-minute interview on September 17, 2021, at 10:10 am ET. Chairman Leonard Mazur will discuss advancements in the company's late-stage clinical pipeline, focusing on I/ONTAK (E7777), a novel oncology asset with potential for near-term revenue and a robust path toward commercial success. Citius is noted for its late-stage candidates, including Mino-Lok®, which is in a Phase 3 trial, and I/ONTAK, having completed enrollment in its pivotal Phase 3 trial.